Outstanding achievements: nearly 70% of China's biopharmaceutical "troika" contribution

[China Pharmaceutical network enterprise news] on March 13, China biopharmaceutical released its 2016 annual performance announcement Among a number of pharmaceutical listed companies that have disclosed their annual reports, this report card of China Bio pharmaceutical is not uncommon According to the announcement, the annual revenue of biopharmaceuticals in China was 15.825 billion Hong Kong dollars, an increase of about 8.8% over 2015 (14.8% in RMB terms), and the profit was about 1.913 billion Hong Kong dollars, an increase of about 7.6% over 2015 (nearly 70% of China's biopharmaceutical "troika" contribution source: Baidu pictures) In addition, according to incomplete statistics, the main subsidiaries of China biopharmaceutical, such as Zhengda Tianqing, Beijing Taide, Nanjing Zhengda Tianqing, Zhengda Fenghai, Zhengda Haier and Zhengda Qingjiang, have a total sales of more than 20 varieties of more than HK $billion, forming a "billion yuan product group" Since 2013, the turnover of China's biopharmaceutical industry has increased continuously in the past three years, reaching HK $12.378 billion, HK $14.55 billion and HK $15.825 billion respectively from 2014 to 2016 In the context of the slowdown of China's overall pharmaceutical economic growth, the growth rate of China's biopharmaceutical revenue in the past three years has maintained a good momentum, showing its considerable strength With 15.825 billion Hong Kong dollars, nearly 70% of China's biopharmaceutical products contributed by Troika cover a wide range of fields, including liver disease medicine, cardiovascular and cerebrovascular medicine, anti-tumor medicine, orthopedic medicine, anti infection medicine, parenteral nutrition medicine, respiratory system medicine, anorectal medicine, etc Among them, liver disease medicine, cardio cerebrovascular medicine and anti-tumor medicine are the three main fields, accounting for nearly 70% of the turnover From 2014 to 2016, the proportion of sales revenue of drugs for liver diseases in total revenue fluctuated slightly, but it still accounted for a large proportion, with a decrease of about 2% in 2016 compared with 2015 In the past two years, the use of cardiovascular and cerebrovascular drugs has fluctuated greatly In 2015, the use of cardiovascular and cerebrovascular drugs accounted for about 9.4% of the total revenue, while in 2016, it rose to 10.2% In 2014-2016, the proportion of anti-tumor drugs increased by 1% annually, accounting for 11.1% of the total revenue in 2016 It can be seen from the data that liver disease medicine, as a traditional advantage field of China's biopharmaceuticals, plays a leading role in the overall revenue At the same time, cardiovascular and cerebrovascular drugs accounted for a large increase in the proportion of revenue, which is particularly noteworthy With the company's increasing investment in the field of anti-tumor drugs, its contribution rate is also rising steadily In addition, according to the sales of main products in recent years, the performances of Runzhong dispersible tablets, Tianqing Ganmei injection and Kaishi Injection are particularly eye-catching, with a total sales volume of more than 7 billion Hong Kong dollars in 2016 Liver disease medication: Runzhong dispersible tablet has reached a new high of HK $3.5 billion Relying on its subsidiary, Zhengda Tianqing, a pioneer in the field of liver disease in China, China biopharmaceutical has become a leading enterprise in the field of liver disease medication in China According to the annual report in recent years, the company has a number of single drugs for liver diseases, including Runzhong dispersible tablets, Tianqing Ganmei injection, Mingzheng capsule, Ganping enteric coated capsule, etc In 2016, the sales volume of drugs for liver diseases was about HK $7.252 billion, accounting for about 45.8% of the group's revenue It can be seen from the data that the sales of Tianqing Ganmei injection and Runzhong dispersible tablet, the main products in the field of liver disease medicine, have been kept above 2 billion Hong Kong dollars for three consecutive years Entecavir is a new generation of oral guanine nucleoside analogues for the treatment of hepatitis B virus infection, which has a very low resistance rate In recent years, the sales volume of the dispersive tablets of Runzhong (entecavir) listed in 2010 has been increasing, with a record high In 2016, the single product sales exceeded HK $3.5 billion In addition, in 2015, among entecavir's manufacturers, Zhengda Tianqing's Runzhong dispersible tablet accounted for 46.81% of the market share of China's public medical institutions (China's urban public hospitals, county-level public hospitals, urban communities, township health centers, four chemical drug terminals), which has surpassed the original manufacturer Shiguibao and ranked first Cardiovascular and cerebrovascular drugs: as the "second elder brother" in the main field of Biopharmaceutics in China for many years, many products have developed steadily in recent years According to the 2016 annual report, the sales volume of cardiovascular and cerebrovascular drugs is about 1.613 billion Hong Kong dollars, accounting for about 10.2% of the group's revenue Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd and Beijing Taide Pharmaceutical Co., Ltd are mainly responsible for the cardiovascular and cerebrovascular drug use of China biopharmaceutical The main products are YIRENPING tablets, tuotuotuo tablets, Kaishi Injection, tianqingning injection, etc It can be seen from the annual report in recent years that, in addition to the slight decline in sales of Kaishi Injection, the sales of Chinese biopharmaceutical cardiovascular and cerebrovascular drug products are relatively stable Among them, elanpine tablets and tuotuotuo calcium tablets kept a steady rise for three consecutive years Antineoplastic drugs: increasing investment in the cultivation potential of anti-tumor drugs is the main battlefield of China's biopharmaceutical industry in recent years, mainly led by Zhengda Tianqing and Nanjing Zhengda Tianqing in R & D and production, and also a potential stock with development space in the future In 2016, the sales volume of China's biopharmaceutical anti-tumor drugs was about HK $1.758 billion, accounting for about 11.1% of the group's revenue, surpassing that of cardiovascular and cerebrovascular drugs for two consecutive years The anti-tumor drugs of China's biopharmaceuticals are mainly developed and produced by Zhengda Tianqing and Nanjing Zhengda Tianqing Among the anti-tumor drug products, Zhiruo injection has a high sales volume of HK $391 million, an increase of about 9.7% compared with the same period in 2015, followed by Tianqing Yitai injection (HK $347 million), saiweijian injection (HK $238 million), first auxiliary tablet (HK $179 million) and qingweike injection (HK $156 million) In recent years, China's biopharmaceuticals have invested heavily in R & D in 2016, R & D investment reached HK $1.599 billion, and anti-tumor drugs are the largest R & D investment It is reported that China's biopharmaceuticals have a total of 438 clinical approvals, ongoing clinical trials, and products under development that have been applied for production, of which 181 are antineoplastic drugs, accounting for a large proportion If the varieties under research progress smoothly, with the enrichment of related products, its market share will further expand, and the tumor mass production group will gradually take shape in the future Conclusion: biopharmaceutical industry in China is one of the enterprises which are good at research and development In recent years, it has achieved sustained and rapid growth of performance by virtue of the stable position of liver disease drugs In the future, with the promotion and implementation of the two vote system, medical insurance fee control, bidding price reduction and other policies, and the acceleration of market restructuring in the pharmaceutical industry, it remains to be seen how China's biopharmaceutical industry, with its outstanding R & D and sales capabilities, can seize the industry's development opportunities.